vs
Axsome Therapeutics, Inc.（AXSM）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是Axsome Therapeutics, Inc.的1.1倍（$217.4M vs $196.0M），Rapid7, Inc.净利率更高（1.4% vs -14.6%，领先16.0%），Axsome Therapeutics, Inc.同比增速更快（65.0% vs 0.5%），Rapid7, Inc.自由现金流更多（$36.4M vs $-18.7M），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（61.7% vs 3.0%）
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
AXSM vs RPD — 直观对比
营收规模更大
RPD
是对方的1.1倍
$196.0M
营收增速更快
AXSM
高出64.5%
0.5%
净利率更高
RPD
高出16.0%
-14.6%
自由现金流更多
RPD
多$55.1M
$-18.7M
两年增速更快
AXSM
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $196.0M | $217.4M |
| 净利润 | $-28.6M | $3.1M |
| 毛利率 | — | 68.9% |
| 营业利润率 | -13.8% | 1.0% |
| 净利率 | -14.6% | 1.4% |
| 营收同比 | 65.0% | 0.5% |
| 净利润同比 | 61.9% | 44.1% |
| 每股收益（稀释后） | $-0.55 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXSMRPD
| Q4 25 | $196.0M | $217.4M | ||
| Q3 25 | $171.0M | $218.0M | ||
| Q2 25 | $150.0M | $214.2M | ||
| Q1 25 | $121.5M | $210.3M | ||
| Q4 24 | $118.8M | $216.3M | ||
| Q3 24 | $104.8M | $214.7M | ||
| Q2 24 | $87.2M | $208.0M | ||
| Q1 24 | $75.0M | $205.1M |
净利润AXSMRPD
| Q4 25 | $-28.6M | $3.1M | ||
| Q3 25 | $-47.2M | $9.8M | ||
| Q2 25 | $-48.0M | $8.3M | ||
| Q1 25 | $-59.4M | $2.1M | ||
| Q4 24 | $-74.9M | $2.2M | ||
| Q3 24 | $-64.6M | $15.4M | ||
| Q2 24 | $-79.3M | $6.5M | ||
| Q1 24 | $-68.4M | $1.4M |
毛利率AXSMRPD
| Q4 25 | — | 68.9% | ||
| Q3 25 | — | 70.2% | ||
| Q2 25 | — | 70.6% | ||
| Q1 25 | — | 71.7% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 70.7% | ||
| Q1 24 | — | 70.3% |
营业利润率AXSMRPD
| Q4 25 | -13.8% | 1.0% | ||
| Q3 25 | -27.0% | 2.7% | ||
| Q2 25 | -24.5% | 1.6% | ||
| Q1 25 | -46.9% | -0.0% | ||
| Q4 24 | -61.1% | 3.4% | ||
| Q3 24 | -59.8% | 6.0% | ||
| Q2 24 | -89.5% | 2.5% | ||
| Q1 24 | -89.7% | 4.7% |
净利率AXSMRPD
| Q4 25 | -14.6% | 1.4% | ||
| Q3 25 | -27.6% | 4.5% | ||
| Q2 25 | -32.0% | 3.9% | ||
| Q1 25 | -48.9% | 1.0% | ||
| Q4 24 | -63.1% | 1.0% | ||
| Q3 24 | -61.7% | 7.2% | ||
| Q2 24 | -91.0% | 3.1% | ||
| Q1 24 | -91.1% | 0.7% |
每股收益（稀释后）AXSMRPD
| Q4 25 | $-0.55 | $0.05 | ||
| Q3 25 | $-0.94 | $0.15 | ||
| Q2 25 | $-0.97 | $0.13 | ||
| Q1 25 | $-1.22 | $0.03 | ||
| Q4 24 | $-1.54 | $0.08 | ||
| Q3 24 | $-1.34 | $0.21 | ||
| Q2 24 | $-1.67 | $0.09 | ||
| Q1 24 | $-1.44 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $322.9M | $474.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $88.3M | $154.7M |
| 总资产 | $689.8M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AXSMRPD
| Q4 25 | $322.9M | $474.7M | ||
| Q3 25 | $325.3M | $407.1M | ||
| Q2 25 | $303.0M | $511.7M | ||
| Q1 25 | $300.9M | $493.5M | ||
| Q4 24 | $315.4M | $521.7M | ||
| Q3 24 | $327.3M | $443.7M | ||
| Q2 24 | $315.7M | $442.6M | ||
| Q1 24 | $331.4M | $411.7M |
股东权益AXSMRPD
| Q4 25 | $88.3M | $154.7M | ||
| Q3 25 | $73.7M | $127.2M | ||
| Q2 25 | $73.1M | $90.4M | ||
| Q1 25 | $53.2M | $52.7M | ||
| Q4 24 | $57.0M | $17.7M | ||
| Q3 24 | $92.9M | $-5.1M | ||
| Q2 24 | $102.9M | $-52.6M | ||
| Q1 24 | $144.0M | $-86.4M |
总资产AXSMRPD
| Q4 25 | $689.8M | $1.7B | ||
| Q3 25 | $669.3M | $1.7B | ||
| Q2 25 | $639.8M | $1.6B | ||
| Q1 25 | $596.7M | $1.6B | ||
| Q4 24 | $568.5M | $1.7B | ||
| Q3 24 | $561.5M | $1.6B | ||
| Q2 24 | $548.2M | $1.5B | ||
| Q1 24 | $545.7M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-18.7M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $-18.7M | $36.4M |
| 自由现金流率自由现金流/营收 | -9.6% | 16.8% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 12.01× |
| 过去12个月自由现金流最近4个季度 | $-93.9M | $146.2M |
8季度趋势，按日历期对齐
经营现金流AXSMRPD
| Q4 25 | $-18.7M | $37.6M | ||
| Q3 25 | $1.0M | $39.0M | ||
| Q2 25 | $-32.4M | $47.5M | ||
| Q1 25 | $-43.4M | $29.8M | ||
| Q4 24 | $-26.2M | $63.8M | ||
| Q3 24 | $-18.6M | $44.0M | ||
| Q2 24 | $-30.1M | $32.9M | ||
| Q1 24 | $-53.5M | $31.1M |
自由现金流AXSMRPD
| Q4 25 | $-18.7M | $36.4M | ||
| Q3 25 | $988.0K | $34.8M | ||
| Q2 25 | $-32.4M | $46.6M | ||
| Q1 25 | $-43.7M | $28.4M | ||
| Q4 24 | $-26.2M | $62.6M | ||
| Q3 24 | $-18.7M | $42.6M | ||
| Q2 24 | $-30.2M | $32.6M | ||
| Q1 24 | $-53.6M | $30.4M |
自由现金流率AXSMRPD
| Q4 25 | -9.6% | 16.8% | ||
| Q3 25 | 0.6% | 16.0% | ||
| Q2 25 | -21.6% | 21.8% | ||
| Q1 25 | -36.0% | 13.5% | ||
| Q4 24 | -22.1% | 28.9% | ||
| Q3 24 | -17.9% | 19.9% | ||
| Q2 24 | -34.6% | 15.7% | ||
| Q1 24 | -71.4% | 14.8% |
资本支出强度AXSMRPD
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 1.9% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.3% | 0.6% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 0.1% | 0.1% | ||
| Q1 24 | 0.1% | 0.3% |
现金转化率AXSMRPD
| Q4 25 | — | 12.01× | ||
| Q3 25 | — | 3.97× | ||
| Q2 25 | — | 5.70× | ||
| Q1 25 | — | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | — | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXSM
暂无分部数据
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
